Cancer medicines

Daratumumab

Daratumumab

A CD38-targeting antibody for multiple myeloma.

Sources checked · Introductory guide

On this page

How it works

It binds CD38 and promotes cancer cell killing through several immune mechanisms.[3]

Where it is used

Used in selected newly diagnosed or relapsed/refractory myeloma. Distinguish the combination and intravenous versus subcutaneous formulations.[1]

Key safety points

Monitor administration reactions and infection. It can affect blood compatibility tests: confirm testing before treatment and disclose its use whenever transfusion is needed.[2]

Questions for your care team

  • How should formulation, infection prevention and pretransfusion records be prepared?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. NCI · Daratumumab (opens in a new tab)
  2. MedlinePlus · Daratumumab (opens in a new tab)
  3. NCI Drug Dictionary · Daratumumab (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

Daratumumab | Cancer Encyclopedia | My Chemo Diary